dickson2u need 3 time limit up then can release me...stay in high floor condo
11/09/2020 4:44 PM

U should average down...because FA is very strong.

geary [CAREPLS]: CAREPLUS GROUP BHD

Sep 10, 2020 4:32 PM | Report Abuse

Added...@2.08.

｡◕‿◕｡
11/09/2020 2:05 PM

Forward PE multiple...#100%... below...#20X.
11/09/2020 2:18 PM

Sold some in Margin...Hold balance with free Cash.

yttihs 8.00 new name = Macquarie block!
11/09/2020 4:34 PM

Power Upswing...Next Week...｡◕‿◕｡

YONG Buy Buy Buy until RM8
11/09/2020 2:34 PM

Already...Limit Up... @8.03...morning session...lowest was...@6.15.

Local funds managers will panic buy back in second session
10/09/2020 1:57 PM

Bought back...@6.18.

Forward PE multiple...#100%... below...#30X.

geary [COMFORT]: COMFORT GLOVES BHD

Sep 10, 2020 4:34 PM | Report Abuse

Bought...@3.28.

｡◕‿◕｡
11/09/2020 2:09 PM

Forward PE multiple...#100%...below...#20X.

geary [CAREPLS]: CAREPLUS GROUP BHD

Sep 10, 2020 4:32 PM | Report Abuse

Added...@2.08.

｡◕‿◕｡
11/09/2020 2:05 PM

Forward PE multiple...#100%... below...#20X.

[CAREPLS]: CAREPLUS GROUP BHD

Sep 10, 2020 4:32 PM | Report Abuse

Added...@2.08.

｡◕‿◕｡

Sean Kelly. CPO. PPE of US.

In the face of the Covid-19 pandemic, a nitrile glove shortage may not seem as dire as a mask shortage. After all, no virus can “drill through the skin on your hand,” and masks are still the best safety precaution for most people.

However, these gloves are still a necessity for medical professionals, tattoo artists, food servers, and mechanics. Plus, they have various at-home uses including gardening, cleaning, and safety precautions for the immunocompromised.
Right now, our supplies are dwindling -- and the United States currently has no domestic manufacturers.

Outside of professional standards, nitrile gloves are sought at the consumer level for their strong resistance to puncture, protection against corrosion and chemicals, and hypoallergenic qualities -
- though some people are allergic, it's far less common than an allergy to latex or other glove-making materials.
We've also previously recommended them for gardening, and they're great for working with fiberglass and harsh cleaning chemicals.

In other words, not everyone needs gloves -- but the people who do need gloves are likely to need nitrile gloves. And they're only going to get harder to find.

“The big problem with the nitrile glove space is that the barrier to entry is so great,” says Sean Kelly, Chief Procurement Officer for PPE of America.
“For surgical masks, also known as 3-ply masks, for $150,000 you can get a machine to make them and you’re in business,
Nitrile glove manufacturing is very complex. The raw materials are very difficult to access in some parts of the world.”

Right now, the only domestic manufacturer of nitrile gloves is The Showa Group. Their factory, in Lafayette, Ala. opens April 12, 2021. And when it comes to amateur glove-making, well, that simply doesn’t exist.

In other words, the deluge of consumer-grade masks we’ve seen -- from fashion companies to individuals starting their own side-hustles on Etsy -- that won’t happen with nitrile gloves. And there’s already starting to be an impact.

"Before Covid, you could buy a box (of nitrile gloves) for $3 - $6," says Kelly. "Go on Amazon now, and you’ll see the average price is $19 - $25, which is ludicrous.”

Exacerbating the problem is the lack of domestic manufacturers, as well as increasing pressure on our foreign providers: In July, the US banned two subsidiaries of the world’s largest glove manufacturer, citing “reasonable evidence of forced labor in the manufacturing process.”

Another problem is fraud, which is especially malignant during the desperation of a public health crisis. Such fraud was a huge problem in the early days of the pandemic: leading N95 mask manufacturer 3M was investigating 4,000 reports of N95 fraud in July, and the Bay Area faced consumer-level fraud in April.

While the biggest problems in procuring nitrile gloves will largely be happening at a corporate, wholesale level, the issues will trickle down to consumers quickly.

“I spoke to a senior buyer in a hospital, and they said that they had literally run out of large nitrile gloves. The glove situation is different with the masks, because with or without Covid, a lot of people need these gloves, but with Covid, they need them more than ever.”

PPE US News.

Stockisnotfun Profit taking. Jump 10% already lo. Volume is getting crazy already. My 8 TP please come back to papa
11/09/2020 12:15 PM

Tired lah...resting...next week the music will be hard rock...◉‿◉

SunTzu1668 Is it time to switch to responsible, trustworthy and transparent IB’s?
11/09/2020 11:58 AM

Money in Chinese character...are two swords fighting...So no way... Human character...Since ancient time...never change.

DreamCommander no cannot take a break when we are advancing & enemy is retreating

we have to crush & obliterate the enemy

we rout them

we annihilate them
11/09/2020 11:55 AM

No...they surrender...must have kindness.

pretty Bullish engulfing again ?
11/09/2020 11:54 AM

Yup...next week will be better...before the Q report...◉‿◉

happ12 tan Sri troops don't go makan first, secure base first
11/09/2020 11:51 AM

Don't worry sold whatever on margin...hold more on cash portfolio...n profit first...makan also happy lah...◉‿◉

Makeabuck all hungry go out early lunch...come back full energy 2:30 push upwards!
11/09/2020 11:42 AM

Yup...early n best lunch today...｡◕‿◕｡

Alipapapa Market sentiment still very volatile.
11/09/2020 11:38 AM

Yup... same same...Good luck...Any Weakness will use margin again.

maggiemee TG dont sailang first.keep some bullet and slap IBs again in case they simply release the TG analyst
11/09/2020 11:33 AM

Yup...Sold some...@8.00...margin account...Hold whatever on Cash...◉‿◉

DreamCommander only another 1.05 to limit up

come on baby you can do it

we give a big hard slap to macquarie's ugly face
11/09/2020 11:06 AM

No need to slap...hpye n lousy FA are temporary...Mr. Market will quote prices accordingly to hype, news, etc...End of the day...it still come back to fundamental...N a good FA counter will rebound the fastest... it's only how U estimate its reasonable price to buy...e.g....What's the intangible value of its brand name... TopGlove...◉‿◉...Tangible are numbers... Intangible is an EQ.

geary.Friendship Foreign funds are coming in to buy cheap and retailers are buying back

Local funds managers will panic buy back in second session
10/09/2020 1:57 PM

Bought back...@6.18.
10/09/2020 2:38PM.

(. ❛ ᴗ ❛.)
11/09/2020 11:00 AM

Yesterday to press the entry button...@6.18...wasn't...Easy at all...Anyway... don't talk 3 talk 4...Just do It...◉‿◉

geary.Friendship Foreign funds are coming in to buy cheap and retailers are buying back

Local funds managers will panic buy back in second session
10/09/2020 1:57 PM

Bought back...@6.18.
10/09/2020 2:38PM.

(. ❛ ᴗ ❛.)

yttihs PAT 1.4 billion!!!

RM12 incoming!!!

Don't miss the bus!!
11/09/2020 9:51 AM

｡◕‿◕｡

Alipapapa this morning made 20k from Topglov.
11/09/2020 9:45 AM

Cash...TA...Gut...Timing...Luck...Win...◉‿◉

geary pBlue Yes, their research can probably be trusted just not their sale team. Their article is misleading in its structure.

If you look carefully at their article, they are taking about a scenario where the glove demand has returned to normal, aka the pandemic has ended. They put that date around FY22.

So once the pandemic is over, and glove demand returns to normal in FY22, Macquarie predicts TG will be able to maintain a TP of RM5.40 (base scenario). Bull scenario it could go as high as RM20.40, with a bear scenario of RM2.80.

Also stated with their article, Macquarie predicts an EPS of RM1.29 for FY2021. Given TG has a 50% dividend policy, it means 64.5 dividend for 2021.

So if we believe Mcquarie... TG is now at a price very near to what it will be able to maintain once the pandemic ends in 2022-2023. And we should expect a dividend of 12sen for this quarter. And 64.5 dividend in FY2021. So people who bought TG today will look forward to a 4% annual dividend for 2020, and 10% dividend for 2021.

And very little down side to their shares once the pandemic ends.

This is the base scenario.

If the glove bull continues.. well TG could rise upto RM20.80... And given the covid19 pandemic is uncontrolled and we are entering flu season... well glove demand will rise as more Covid19 patients flood the hospitals.

Yeah i know... TA people will call me foolish for believing in FA. But there you go.

If everyone throw their TG shares tomorrow, I will be around to buy as much as I can... i mean... 10% dividend per year? Who can say no to that?

Posted by lclwyp > Sep 10, 2020 4:16 PM | Report Abuse
On 26/8/20, Macquarie gave TP 30.40. Now (2 weeks later), almost cut half to 16.20 (5.40 x3)
Their research can be trusted?
10/09/2020 5:14 PM

Thanks.@pBlue.
TA wise very Simple...#10.30am...alrrady below RSI30...Oversold...almost all genuine glove counters...So the possibility of a Technical Rebound is high...So maybe tomorrow is Friday...looking bearish...but we never know... Malaysia Boleh...⊙﹏⊙
10/09/2020 6:11 PM

｡◕‿◕｡

supersinginvestor Looks like even big boss cant help or protect topglove... good luck guys... now its all about luck...
10/09/2020 7:06 PM

It's not really all luck...looking at present scenario...I think it's already undervalued at present market value.

joecool32 TG's orderbook backlog = 18mths, Adv payment = 900m and macquarie says end of game by 2021? if TG makes 3b next 2-3 qr, they have no intelligent way of investing it in r&d and other innovations? what kind of financial modelling tells you to ignore the next 5 qrs and downgrade the TP for a simplistic fcst that growth would be slower.........

We're talking new normal but got analyst using old world scenarios to scare ppl. Why don't they upgrade airline industry saying that by end 2021, tourism would become robust again and up Airline TP by 30%........... Furthermore, TG was not even interviewed regarding growth sustainability beyond fy2021. Such a major assumption and TG's mgnt input was not sought out at all. The intention is clearly to hurt the stock price.......
10/09/2020 7:01 PM

With so much uncertainties...taking more than 1 year...of assumptions...huge Margin of Errors.

supersinginvestor Wow so much sharebuy bak yet fall like shiit... cant imagine why.. looks like ibs throwing n no hope....
10/09/2020 6:54 PM

Unless u sapu all the public shares...around 18.88 Billions...at present market value.

Steviaman Ban Macquarie. Cant afford lose dont issue warrant la. Now all warrant issued also high premium 1
10/09/2020 6:34 PM

Genuine investors don't play or buy derivatives such as warrant, option, future, etc.

ant888 https://klse.i3investor.com/blogs/glovesvsvaccine/2020-09-10-story-h1513433504-Macquarie_s_TOP_GLOVE_call_look_at_the_facts_and_draw_your_own_conclusi.jsp

idiot analyst in Macquarie...
10/09/2020 6:29 PM

They aren't idiots...they are very cunning...they sold...now want to buy back...so they do some fire lah...later put some water lah...when they bought enough.

Jingweihan Tg angry already!
10/09/2020 6:27 PM

More sell down...more buybacks...so next time boss give us some treasury shares also good.

Immediate Announcement on Shares Buy Back
TOP GLOVE CORPORATION BHD

Date of buy back 10 Sep 2020
Description of shares purchased Ordinary Shares
Currency Malaysian Ringgit (MYR)
Total number of shares purchased (units) 14,930,000
Minimum price paid for each share purchased ($$) 6.120
Maximum price paid for each share purchased ($$) 7.400
Total consideration paid ($$) 99,934,285.00
Number of shares purchased retained in treasury (units) 14,930,000
Number of shares purchased which are proposed to be cancelled (units) 0
Cumulative net outstanding treasury shares as at to-date (units) 18,306,800
Adjusted issued capital after cancellation
(no. of shares) (units) 8,133,314,774
Total number of shares purchased and/or held as treasury shares against total number of issued shares of the listed issuer (%) 0.22508

Announcement Info
Company Name TOP GLOVE CORPORATION BHD
Stock Name TOPGLOV
Date Announced 10 Sep 2020
Category Immediate Announcement on Shares Buy Back
Reference Number SB1-09092020-00011

Hotstuff 100m share buyback lol. tan Sri must be very confident on the upcoming qr
10/09/2020 6:19 PM

TopGlove balance sheet very strong...then u think Bursa will approve 2:1. Need lot of money u know. Share split no need money.

GiantPanda.That’s how the crook evil IBs con cheat retail investors, twist and spin Buy and Sell calls to benefit their big clients only

Boycott all MACQUARIE call warrants!!!

Ban all Call Warrants!!!

How could useless Bursa and SC let evil IBs issue call warrants on other companies to encourage gambling??

KARMA WILL HIT THOSE EVIL ONES VERY HARD
10/09/2020 6:10 PM

Stock markets...All Mr. Markets are like this n like that...this is a stock markets...

pBlue Yes, their research can probably be trusted just not their sale team. Their article is misleading in its structure.

If you look carefully at their article, they are taking about a scenario where the glove demand has returned to normal, aka the pandemic has ended. They put that date around FY22.

So once the pandemic is over, and glove demand returns to normal in FY22, Macquarie predicts TG will be able to maintain a TP of RM5.40 (base scenario). Bull scenario it could go as high as RM20.40, with a bear scenario of RM2.80.

Also stated with their article, Macquarie predicts an EPS of RM1.29 for FY2021. Given TG has a 50% dividend policy, it means 64.5 dividend for 2021.

So if we believe Mcquarie... TG is now at a price very near to what it will be able to maintain once the pandemic ends in 2022-2023. And we should expect a dividend of 12sen for this quarter. And 64.5 dividend in FY2021. So people who bought TG today will look forward to a 4% annual dividend for 2020, and 10% dividend for 2021.

And very little down side to their shares once the pandemic ends.

This is the base scenario.

If the glove bull continues.. well TG could rise upto RM20.80... And given the covid19 pandemic is uncontrolled and we are entering flu season... well glove demand will rise as more Covid19 patients flood the hospitals.

Yeah i know... TA people will call me foolish for believing in FA. But there you go.

If everyone throw their TG shares tomorrow, I will be around to buy as much as I can... i mean... 10% dividend per year? Who can say no to that?

Posted by lclwyp > Sep 10, 2020 4:16 PM | Report Abuse
On 26/8/20, Macquarie gave TP 30.40. Now (2 weeks later), almost cut half to 16.20 (5.40 x3)
Their research can be trusted?
10/09/2020 5:14 PM

Thanks.@pBlue.
TA wise very Simple...#10.30am...alrrady below RSI30...Oversold...almost all genuine glove counters...So the possibility of a Technical Rebound is high...So maybe tomorrow is Friday...looking bearish...but we never know... Malaysia Boleh...⊙﹏⊙

Bought...@3.28.

Added...@2.08.

Friendship Foreign funds are coming in to buy cheap and retailers are buying back

Local funds managers will panic buy back in second session
10/09/2020 1:57 PM

Bought back...@6.18.

TOP GLOVE buyback 1.392million shares at RM7.11 - RM7.21
Author: gloveharicut Publish date: Wed, 9 Sep 2020, 7:26 PM

{{{PM me to join GLOVE Private Discussion Room}}}

I invite you to read my blog and make a smart GLOVE decision.

https://klse.i3investor.com/blogs/gloveharicut/blidx.jsp

TOP GLOVE buyback 1.392million shares at RM7.11 - RM7.21

https://klse.i3investor.com/insider/company/shareBuyback/7113/09-Sep-2020/69436_1164386400.jsp

#Efficient Management.

2020 SEP 8.
GENEVA - World Health Organization chief Tedros Adhanom Ghebreyesus said on Monday the world must be better prepared for the next pandemic, as he called on countries to invest in public health.

More than 27.19 million people have been reported to be infected by the novel coronavirus globally and 888,326​ have died, according to a Reuters tally, since the first cases were identified in China in December 2019.

"This will not be the last pandemic," Tedros told a news briefing in Geneva. "History teaches us that outbreaks and pandemics are a fact of life. But when the next pandemic comes, the world must be ready – more ready than it was this time."

REUTERS.

2020 SEP 8.
GENEVA - World Health Organization chief Tedros Adhanom Ghebreyesus said on Monday the world must be better prepared for the next pandemic, as he called on countries to invest in public health.

More than 27.19 million people have been reported to be infected by the novel coronavirus globally and 888,326​ have died, according to a Reuters tally, since the first cases were identified in China in December 2019.

"This will not be the last pandemic," Tedros told a news briefing in Geneva. "History teaches us that outbreaks and pandemics are a fact of life. But when the next pandemic comes, the world must be ready – more ready than it was this time."

REUTERS.

Chinese made Vaccines.

https://www.globaltimes.cn/content/1200192.shtml

Be Realistic...(｡◕‿◕｡)➜

https://www.theguardian.com/commentisfree/2020/sep/06/lets-get-real-no-vaccine-will-work-as-if-by-magic-returning-us-to-normal

China Vaccine News.

Indonesia has secured a commitment to be sent 20-30 million doses of the potential vaccine by the end of this year, some 80-130 million doses in first quarter of next year and 210 million doses for the remainder of 2021, she said.

“Therefore, if we talk about numbers, we have secured 290 million to 340 million for 2021,” she told reporters in a virtual briefing on Monday.

The first of the deals were secured when the two ministers visited China’s resort city Sanya on Hainan Island on Thursday, while the rest were negotiated with UAE officials in Abu Dhabi on Saturday.

In Sanya, Retno and Erick oversaw two deals between state-owned pharmaceuticals firm Bio Farma and China’s Sinovac Biotech that would give Indonesia the equivalent of 50 million doses of the potential vaccine from November to March and priority access for the rest of 2021.

Read also: Government, Bio Farma secure vaccine bulk supply from China's Sinovac

It will be supplied in the form of vaccine bulk, an aqueous form of the purified antigens, or vaccine, provided in a large container from which individual vials are filled.

Indonesia is already cooperating with Sinovac in the phase three clinical trial of the vaccine candidate, with tests being carried out on 1,620 volunteers in Bandung, West Java, since earlier this month.

The government has also looked into partnerships with two other Chinese drug manufacturers, SINOPHARM and CanSino Biologics.

BBIBP-CorV (Sinopharm/CNBG, China)

Now we’re into “old school” inactivated vaccines that are in phase 3 trials. Clinical trial data hasn’t been published here yet. I’ve seen BBIBP-CorV discussed as 1 or 2 vaccines, so I could be wrong here: I’m assuming it’s 2.

Sinopharm is state-run, with a corporate subsidiary, the China National Biotec Group (CNBG). BBIBP-CorV vaccine(s) has/have been through a phase 1/2 trial, with 1,120 people.

CNBG posted some interim results on their website in June, which reports positive antibody responses, but no detail on adverse effects. It has reportedly been said that adverse effects will be lower than other vaccines – which would not be surprising for inactivated vaccine.

The phase 3 trial is underway in Abu Dhabi, United Arab Emirates (UAE). UAE was reporting about 500 people or so with new confirmed Covid-19 a day in June, according to Wikipedia. It’s a country of about 10 million people. So there’s some virus circulating.

If I’m understanding the trial registry entry properly, this will surely be the first phase 3 trial with interim results. The trial measures effectiveness in protecting against infection just 14 days after the 2-injection vaccination course is completed.

Its for 15,000 adults with no upper age limit, with 2 groups of 5,000 people for each vaccine and a 5,000-person placebo group.
(It’s not specified what each of the 2 groups are, but it’s why I’m assuming there are 2 vaccines.)

China can reportedly produce 200 million or more doses of this vaccine a year, including using a new production facility that was scheduled for completion at the end of July.

A production deal has also been reported between UAE/China and Indonesia.

Those countries are Muslim majority and it's Halal. Malaysia probably will follow as per normal.

yanz77 Titijaya should at least issue a press statement regarding their involvement with Sinopharm and their future plans if a vaccine from Sinopharm is successfully produced. At least this could convince their investors.
06/09/2020 2:15 PM

If announce tonight... tomorrow limit up..n three days limit up...u have chance to buy at what Price...◉‿◉

Sinopharm vaccine from China arrives in Peru for clinical trial
Updated 2020.09.05 13:39 GMT+8

A coronavirus vaccine candidate from the Chinese pharmaceutical company Sinopharm arrived in Lima this Wednesday for the all-important Phase Three clinical trial.

Sinopharm's vaccine testing samples arrive in Peru.
Indonesia begins last phase of vaccine clinical trials.

As early in July, emergency used of Sinopharma vaccine for Sinopharmas' laboratory workers n other vaccines are involved like CanSino n Sinovac.

Sinopharma vaccine will finish its phase 3 trials by year end. And approved by China health authority.

China vaccine News.

Dr Altice highlighted three important requirements for Covid-19 vaccines — safety, efficacy and the manufacturing process.

The produced vaccine should be safe and work well without causing side effects. He also explained the three important phases in Covid-19 vaccine development process.

“The phases are Phase One, which is safety. This like the Moderna vaccine — about 10 patients or so, where we find the lowest dose required to produce the maximum antibody, that is immune response in healthy volunteers.

Phase Two involves patients in the hundreds and we ask the question how well is that vaccine working and those who need it.

“And then Phase Three is the classic randomised control trial that will take thousands of patients and it really asks the question for those who get exposed, is there a reduction in the likelihood of getting infected and how much of a reduction is there,”
said Dr Altice at the talk titled “#VirtualTalk UM and Yale: The Race to Covid’s End”.

He also mentioned that a wide range of tests should be done involving the elderly and children to study the effectiveness of a vaccine to develop immunity against the virus that causes Covid-19, as well as to avoid unintended consequences.

“There are some really important issues because this disease impacts more negatively those individuals who are older and who have immune compromised,” he said.

Furthermore, Dr Altice raised storage problems that will probably emerge in Covid-19 vaccination.

Usually, most vaccines for common conditions can be stored in refrigerators at home here. Those vaccines are easier to be delivered all over the world, including equatorial regions where Malaysia is located. But Covid-19 belongs to the family of single-stranded ribonucleic acid (RNA) viruses.

Unlike conventional vaccines, RNA vaccines should be stored at very low temperatures, said Dr Altice.

“The problem is that our experience with most RNA vaccines, which this will be most likely, have to be stored at incredibly low levels minus 80 degrees, which are typically research freezers, and it will be inaccessible for much of the world,” he said.

“So that’s a major sort of issue and then of course I would say we have to really think about prioritising who gets it.

“The places that will be most devastated will be the low and middle-income countries where there’s a lack of hospital beds and a lack of medical infrastructure to take care of people who get sick.”

He stressed that the producer of vaccines and cost are crucial factors to ensure the vaccine reaches those who really need it.

BBC reported.

Dr Altice highlighted three important requirements for Covid-19 vaccines — safety, efficacy and the manufacturing process.

The produced vaccine should be safe and work well without causing side effects. He also explained the three important phases in Covid-19 vaccine development process.

“The phases are Phase One, which is safety. This like the Moderna vaccine — about 10 patients or so, where we find the lowest dose required to produce the maximum antibody, that is immune response in healthy volunteers.

Phase Two involves patients in the hundreds and we ask the question how well is that vaccine working and those who need it.

“And then Phase Three is the classic randomised control trial that will take thousands of patients and it really asks the question for those who get exposed, is there a reduction in the likelihood of getting infected and how much of a reduction is there,”
said Dr Altice at the talk titled “#VirtualTalk UM and Yale: The Race to Covid’s End”.

He also mentioned that a wide range of tests should be done involving the elderly and children to study the effectiveness of a vaccine to develop immunity against the virus that causes Covid-19, as well as to avoid unintended consequences.

“There are some really important issues because this disease impacts more negatively those individuals who are older and who have immune compromised,” he said.

Furthermore, Dr Altice raised storage problems that will probably emerge in Covid-19 vaccination.

Usually, most vaccines for common conditions can be stored in refrigerators at home here. Those vaccines are easier to be delivered all over the world, including equatorial regions where Malaysia is located. But Covid-19 belongs to the family of single-stranded ribonucleic acid (RNA) viruses.

Unlike conventional vaccines, RNA vaccines should be stored at very low temperatures, said Dr Altice.

“The problem is that our experience with most RNA vaccines, which this will be most likely, have to be stored at incredibly low levels minus 80 degrees, which are typically research freezers, and it will be inaccessible for much of the world,” he said.

“So that’s a major sort of issue and then of course I would say we have to really think about prioritising who gets it.

“The places that will be most devastated will be the low and middle-income countries where there’s a lack of hospital beds and a lack of medical infrastructure to take care of people who get sick.”

He stressed that the producer of vaccines and cost are crucial factors to ensure the vaccine reaches those who really need it.

BBC reported.

World COVID-19.
Surgical glove makers struggle to keep pace with booming demand
(Top Gloves/Anas Zakwan/Handout via Reuters)
04 Sep 2020 11:42PM
(Updated: 05 Sep 2020 11:43PM)

Worldwide: With no end in sight to the coronavirus pandemic, worldwide demand for surgical gloves - as for other types of personal protective equipment - is booming, leaving manufacturers struggling to keep up.

The global PPE market - from masks, gowns and gloves, to shoes and sanitising gels - is expected to balloon from US$52 billion in 2019 to US$93 billion in 2027, according to German market data specialist, Statista.

And, like other such products that were previously predominantly the domain of specialist medical personnel, the surgical glove has become much sought after even by the general public.

US-based Allied Market Research estimates that the global disposable gloves market amounted to US$6.8 billion in 2019, and is expected to nearly triple to US$18.8 billion by 2027.

Worldwide demand for personal protective equipment is booming as a result of the coronavirus
Worldwide demand for personal protective equipment is booming as a result of the coronavirus pandemic.

Just as worldwide shortages of masks and disinfectant gels have pushed up the prices of those products, single-use medical gloves have become increasingly difficult and costly to come by during the health crisis.

"We have health centres calling us every day trying to get their hands on gloves," said Sebastien Lenoble, director of Netherlands-based Shield Scientific, which markets gloves for medical, industrial and laboratory applications.

"These aren't our usual clients. They're coming to us because they're desperate to find gloves."

While the World Health Organization says that wearing rubber or latex gloves in public offers little protection against infection, they are becoming an increasingly common sight in shops and public transport around the world.

"We are observing a more than threefold increase in demand for examination gloves, and demand for surgical gloves has also increased significantly," said Monika Riedel, spokeswoman for Austrian company Semperit, whose Sempermed subsidiary makes between seven and eight billion gloves every year.

Malaysia is the world's biggest maker of rubber gloves, accounting for around 60 per cent of global exports.

CNN News.

Malaysia's glove makers struggle to meet booming demand
By AFP
September 5, 2020 @ 10:00am
- NSTP / FAIZ ANUAR

PARIS: With no end in sight to the coronavirus pandemic, worldwide demand for surgical gloves – as for other types of personal protective equipment – is booming, leaving manufacturers struggling to keep up.

The global PPE market – from masks, gowns and gloves, to shoes and sanitising gels – is expected to balloon from US$52 billion in 2019 to US$93 billion in 2027, according to German market data specialist, Statista.

And, like other such products that were previously predominantly the domain of specialist medical personnel, the surgical glove has become much sought after even by the general public.

US-based Allied Market Research estimates that the global disposable gloves market amounted to US$6.8 billion in 2019, and is expected to nearly triple to US$18.8 billion by 2027.

Covid-19: Malaysia's Top Glove overwhelmed by international orders
Spike in demand for rubber gloves: Top Glove to the rescue
Top Glove now Malaysia's second-biggest company
Just as worldwide shortages of masks and disinfectant gels have pushed up the prices of those products, single-use medical gloves have become increasingly difficult and costly to come by during the health crisis.

Malaysia is the world's biggest maker of rubber gloves, accounting for around 60 per cent of global exports.

And according to the Malaysian manufacturers' association MARGMA, worldwide demand is projected to rise from 296 billion in 2019 to 330 billion this year.

Given the surge, the industry is forecasting a shortage that is expected to last well into next year, MARGMA said.

Malaysian manufacturer Top Glove, which describes itself as the world's biggest producer of rubber gloves, said it is seeing orders for 11-12 billion a month, compared with 4.5 billion prior to the pandemic.

As a result, customers must now wait nearly 600 days for their orders to be filled, compared with a normal delivery time of 30-40 days, said chief executive, Lim Wee Chai.

In addition, with raw materials in short supply, production costs are also rising.

"The shortage of raw material for our nitrile gloves and the disruption to the supply or production of other material such as packaging materials due to the global lockdown, has caused an increase in the production cost," said Top Glove.

That would be passed on to customers in the form of higher prices.

While health experts argue that regular handwashing offers better protection against Covid-19 than gloves, the current boom for PPE is expected to pose another problem further down the line.

Environmental campaigners are concerned that millions of tonnes of single-use gloves will end up polluting the oceans.

- AFP.
05/09/2020 1:31 PM

Malaysia's glove makers struggle to meet booming demand
By AFP
September 5, 2020 @ 10:00am
- NSTP / FAIZ ANUAR

PARIS: With no end in sight to the coronavirus pandemic, worldwide demand for surgical gloves – as for other types of personal protective equipment – is booming, leaving manufacturers struggling to keep up.

The global PPE market – from masks, gowns and gloves, to shoes and sanitising gels – is expected to balloon from US$52 billion in 2019 to US$93 billion in 2027, according to German market data specialist, Statista.

And, like other such products that were previously predominantly the domain of specialist medical personnel, the surgical glove has become much sought after even by the general public.

US-based Allied Market Research estimates that the global disposable gloves market amounted to US$6.8 billion in 2019, and is expected to nearly triple to US$18.8 billion by 2027.

Covid-19: Malaysia's Top Glove overwhelmed by international orders
Spike in demand for rubber gloves: Top Glove to the rescue
Top Glove now Malaysia's second-biggest company
Just as worldwide shortages of masks and disinfectant gels have pushed up the prices of those products, single-use medical gloves have become increasingly difficult and costly to come by during the health crisis.

Malaysia is the world's biggest maker of rubber gloves, accounting for around 60 per cent of global exports.

And according to the Malaysian manufacturers' association MARGMA, worldwide demand is projected to rise from 296 billion in 2019 to 330 billion this year.

Given the surge, the industry is forecasting a shortage that is expected to last well into next year, MARGMA said.

Malaysian manufacturer Top Glove, which describes itself as the world's biggest producer of rubber gloves, said it is seeing orders for 11-12 billion a month, compared with 4.5 billion prior to the pandemic.

As a result, customers must now wait nearly 600 days for their orders to be filled, compared with a normal delivery time of 30-40 days, said chief executive, Lim Wee Chai.

In addition, with raw materials in short supply, production costs are also rising.

"The shortage of raw material for our nitrile gloves and the disruption to the supply or production of other material such as packaging materials due to the global lockdown, has caused an increase in the production cost," said Top Glove.

That would be passed on to customers in the form of higher prices.

While health experts argue that regular handwashing offers better protection against Covid-19 than gloves, the current boom for PPE is expected to pose another problem further down the line.

Environmental campaigners are concerned that millions of tonnes of single-use gloves will end up polluting the oceans.

- AFP
05/09/2020 12:43 PM
05/09/2020 1:31 PM